All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HT-003
Therapeutic Area: Gastroenterology Product Name: HT-003
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2021
Details:
Fresh explants of ulcerative colitis and Crohn's disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Hatteras Venture
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 01, 2021
Details:
Artizan will use the proceeds to continue advancing the preclinical research and development of its lead program for inflammatory bowel disease (“IBD”), which is anticipated to enter the clinic in 2022, as well as to explore additional disease targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: $481.0 million Upfront Cash: $44.0 million
Deal Type: Collaboration December 20, 2020
Details:
GSK licenses global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR® technology and structure-based drug design platform. The licensed products includes an advanced lead preclinical drug as well as multiple differentiated back-up compounds.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Gastroenterology Product Name: PGN-001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
Progenity has two lead drug-device candidates utilizing the DDS technology, PGN-001, a high-concentration formulation of adalimumab, and PGN-600 a liquid formulation of tofacitinib, both under development for the treatment of ulcerative colitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Allocetra
Therapeutic Area: Gastroenterology Product Name: Allocetra
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Upon issuance, the new patent will provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PN-235
Therapeutic Area: Gastroenterology Product Name: JNJ-77242113
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 29, 2020
Details:
The two new candidates, PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186), are being developed as part of a portfolio strategy of discovering and developing oral IL-23 receptor antagonists.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BX002
Therapeutic Area: Gastroenterology Product Name: BX002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing bacteria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SNSP003
Therapeutic Area: Gastroenterology Product Name: SNSP003
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: CF Foundation
Deal Size: $22.5 Million Upfront Cash: $14.0 million
Deal Type: Funding October 20, 2020
Details:
The new funding will be used to advance preclinical development and early stage clinical trials for Synspira’s non-porcine enzyme replacement therapy, SNSP003.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALV-304
Therapeutic Area: Gastroenterology Product Name: ALV-304
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Funding October 05, 2020
Details:
The funds will support Alivio’s preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RTX-1688
Therapeutic Area: Gastroenterology Product Name: RTX-1688
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Rodeo Therapeutics nominates Candidate RTX-1688, a first-in-class oral small molecule therapy for tissue regeneration and repair, with inflammatory bowel disease as the initial indication and platform potential in other disease settings .
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
